VA-ECMO Cardioprotection Using Mitochondrial Protective Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for myocardial infarction using veno-arterial extracorporeal membrane oxygenation (VA-ECMO) result in high in-hospital mortality and limited survival without heart transplantation, due to myocardial damage caused by tafazzin depletion, cardiolipin loss, and increased iAAA protease activity in cardiac muscle cells.
Innovation Solution
Administering a cardioprotective agent, such as a mitochondrial protective agent or antioxidant, before or during ECMO treatment, and optionally combining it with left ventricular decompression, to restore or maintain tafazzin levels and stabilize cardiolipin, thereby reducing myocardial damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If VA-ECMO is used to provide circulatory support in AMI patients, then circulatory and respiratory support is achieved, but myocardial damage increases due to tafazzin depletion and cardiolipin loss
Solution Approach 1:
The patent applies preliminary anti-action by administering cardioprotective agents (mitochondrial protective agents, antioxidants, anti-apoptotic agents) before ECMO treatment begins. These agents pre-protect the myocardium against the harmful effects of ECMO-induced tafazzin depletion and cardiolipin loss, thereby reducing myocardial damage while maintaining the necessary circulatory support function
Solution Approach 2:
The patent uses cardioprotective agents as intermediaries between the ECMO system and the myocardium. These agents mediate the interaction by counteracting the harmful biochemical effects (tafazzin depletion, cardiolipin loss, oxidative stress) that would otherwise directly damage cardiac muscle cells during ECMO treatment
2Reliability
If reperfusion is performed rapidly to treat AMI, then mortality is reduced, but myocardial injury is accelerated due to reperfusion injury
Solution Approach 1:
The patent applies preliminary action by delivering cardioprotective agents to the myocardium before reperfusion occurs. This pre-treatment allows the protective mechanisms to be in place before the reperfusion event, enabling rapid reperfusion to be performed while the myocardium is already protected against reperfusion injury
Solution Approach 2:
The patent uses cardioprotective agents as a cushioning mechanism that is established beforehand. These agents create a protective buffer against the oxidative stress and cellular damage that would normally occur during reperfusion, allowing rapid reperfusion to proceed safely
3Quantity of substance
If cardioprotective drugs are delayed to allow drug delivery, then drug reaches the area at risk, but myocardial damage increases due to prolonged ischemia
Solution Approach 1:
The patent uses the ECMO circuit as an intermediary delivery system for cardioprotective drugs. By incorporating drug delivery into the ECMO blood circulation system, drugs can be administered efficiently through the extracorporeal circuit, achieving rapid and effective drug delivery to the myocardium without requiring delays in ECMO initiation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduces infarct size, stabilizes electron transport chain function, and decreases oxidative stress, improving survival outcomes and reducing myocardial damage during ECMO treatment.
Implementation Method 1
decreases oxidative stress, improving survival outcomes and reducing myocardial damage during ECMO treatment
Data Source
AI summary
The invention provides methods, compositions, systems, and kits for use in reducing or preventing myocardial damage due to extracorporeal membrane oxygenation.